Ovarian cancer is a major cause of cancer related death among women. The disease is usually advanced at diagnosis, because specialist referral is delayed due to vague nature of presenting symptoms. Primary treatment is successful, but most patients experience recurrence. Complaints due to disease and therapy overlap. Furthermore treatment schedules are similar in response rate and survival rates. Toxicity of therapy as scored by the physician is best documented, but varies depending on type of chemotherapy. Moreover most knowledge is acquired in clinical trials and not in daily practice. Patient reported outcome (PROs) concerning effects on symptoms, velocity of relief and quality of life (QoL) by the different regimens is sparce. Also it is unknown which symptoms are best relieved. Most trials take into account progression or survival as primary endpoint but not often symptom relief, which is especially important for patients with recurrent disease, without no chance of cure anymore. Knowledge on rating of problems and needs of patients with recurrent ovarian cancer (ROC) to support them in the course of their disease is needed to come to an evidence based and patient centered treatment of choice together with the patient. Physicians most frequently use the Common Toxicity Criteria (CTC) scale for grading of side effects of treatment, but discrepancies with patient experiences is high. Routine collection of PROs may therefore improve patient expectations and management. In this project the investigators intend to augment knowledge by PROs of different chemotherapy schedules for recurrent ovarian cancer in order to improve shared decision making with the physician. Objective: primary objective of this project is to explore the relief of symptoms due to ROC, the speed with which this occurs by different chemotherapy schedules and development of complaints due to the regimen of chemotherapy. Secondary the investigators intend (1) to assess preferential symptom relief by patients, (2) to correlate toxicity and symptoms of disease to tumor assessed response to chemotherapy and (3) to correlate symptom relief by psychosocial context.
Study Type
OBSERVATIONAL
Enrollment
360
Velocity of disease symptom relief and its duration by systemic therapy measured by change in MOST questionnaires on PROs and response to therapy
Time frame: Change in MOST questionnaires as measured before start of therapy, at week 3, 6, 9 and 18 and and there after every 3 months until progression or 1 year
Change in patient reported disease symptoms top 3 due to systemic therapy on their top 3 of complaints
Time frame: change measured by questionnaire before start of therapy, at week 9 and 18 and at time of progression or 1 year
Change in top 3 complaints due to chemotherapy
Time frame: change measured by questionnaire before start of therapy, at week 9 and 18 and at time of progression or 1 year
Change in patient reported psychosocial wellbeing
Time frame: Change measured by HADS questionnaires before start of therapy, at week 9 and 18 and at time of progression or 1 year
Change in patient reported empowerment
Time frame: Change measured by NEV questionnaire before start of therapy, at week 9 and 18 and at time of progression or 1 year
Change in patient reported needs
Time frame: Change measured on CASUN questionnaire before start of therapy, at week 9 and 18 and at time of progression or 1 year
Response to therapy by CA-125 (according to GCIG criteria and radiology by RECIST 1.1 criteria)
Time frame: change measured before start of therapy, at week 9 and 18 and at time of progression or 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.